Upcoming Events
We are excited to attend the Alzheimer’s Association International Conference 2026, taking place in London, where leading researchers, clinicians and industry experts will come together to discuss the latest advances in dementia science.
Priavoid will present five poster contributions at AAIC 2026, highlighting progress across our clinical and preclinical work in Alzheimer’s disease and other neurodegenerative disorders.
Our poster presentations include:
A-beta Oligomer Lowering Treatment with PRI-002 Does Not Cause ARIA in Ongoing Phase 2 Trial
- Presented by: Oliver Peters, CMO
- Poster Number: Monday-1173
Design of a Phase 2 Study (PRImus-AD) Treating Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease
- Presented by: Dagmar Jürgens, Director Clinical Development
- Poster Number: Wednesday-0048
The Aβ Targeting Compound PRI-002 Reduces Aβ Oligomers and Prevents Cognitive Decline in Various AD Animal Models
- Presented by: Sarah Schemmert, Director Program Management
- Poster Number: Wednesday-0042
A Placebo-controlled, Double-blind, Phase 1b Study to Evaluate Safety and Pharmacodynamics of Orally Applied PRI-002 in Early AD
- Presented by: Dieter Willbold, CSO
- Poster Number: Tuesday-0023
Development of all-D-peptides for the Disassembly of Toxic Tau Aggregates
- Presented by: Antje Willuweit, Director Preclinical Development
In addition to the presenting team members, Priavoid’s CEO Philipp Bürling and our colleague Kira Allmeroth will also be attending the conference.
We look forward to connecting with the Alzheimer’s community at AAIC 2026 and discussing Priavoid’s differentiated, orally available all-D-peptide compounds, our unique detangler approach, and the disease-modifying potential of targeting neurotoxic protein aggregates at their biological roots.
If you are attending AAIC 2026 and would like to learn more about Priavoid’s work, please feel free to get in touch via media@priavoid.com.
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.